Newsroom – SyneuRx

Press Release

Sep 14, 2023

SyneuRx CEO Emil Tsai Publishes a Research Article in The Lancet Regional Health – Western Pacific, Indicating a Sharp Increase in Suicide Attempts During the COVID-19 Pandemic in French Polynesia

Dec 08, 2022

SyneuRx CEO Emil Tsai Named Fellow of National Academy of Inventors

July 31, 2022

SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

July 25, 2022

Dr. Joseph T. Coyle Named Chair of SyneuRx’s Scientific Advisory Board

Apr 13, 2022

SyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

Jan 6, 2022

SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants

Publication

April, 2024

The Development of a Regulator of Human Serine Racemase for N-Methyl-D-aspartate Function

Feb, 2024

Fabrication of nanocrystal forms of ᴅ-cycloserine and their application for transdermal and enteric drug delivery systems

Dec, 2023

Ultrapure and potent tannic acid (UPPTA) is a novel inhibitor of D-amino acid oxidase to improve the N-methyl-D-aspartate function of CNS disorders

Nov, 2023

Toxicological evaluation of Ultrapure and Potent Tannic Acid (UPPTA) by inhalation exposure

July, 2022

SyneuRx Published a Research Paper in《Journal of Alzheimer's Disease Reports》with Disease-modifying Medication Results of Lithium Benzoate, Which was Demonstrated as a Safe and Effective Drug Candidate for Alzheimer's Disease or other Neurodegenerative Disorders. (Accepted)

Media

Nov 18, 2022

Why Fentanyl Vaccine Could Be a Game Changer for Opioid Epidemic

“Just because we are seeing this breakthrough through an animal-based study does not mean that its efficacy will transfer to humans,” Dr. Emil Tsai, a neuroscientist and founding chief executive officer of biotech developer SyneuRx, told Healthline. “The biological divergence between the species can lead to unreliable results in the transfer.

“That unknown aside, there are a few points within the study that I am dubious about,” Tsai said. “It’s unclear why the results were more effective for male rats than for female rats. In addition, the decision to make this drug only respond to fentanyl does little to combat those who are addicted to opioids, as this leaves the possibility for them to seek out other opioid drugs.”

Tsai said the vaccine only addresses one part of recovery.

“It’s important to treat the entire scope of the addiction,” Tsai said. “Relying on biological methods is a piecemeal solution. It does not address the entire problem. Those who are reliant on drugs or alcohol need counseling and mental wellness for healing.”

Oct 28, 2022

Dr. Tsai shared his commentary about the relationship of dementia and blood pressure and was quoted several times in the article.

Oct 14, 2022

Dr. Tsai shared his commentary about accurate COVID-19 death, and SyneuRx was mentioned.

Oct 12, 2022

Dr. Tsai shared his commentary regarding the new study of ketamine on depression. SyneuRx's website was linked to this article.

Oct 04, 2022

Forbes. Dr. Tsai was interviewed and shared his commentary regarding the polio.

"No polio cases have been caused by wild poliovirus originating in the U.S. since 1979 until recently when poliovirus was confirmed in an unvaccinated, [healthy] adult resident of New York,” explains Emil Tsai, M.D., a professor at the David Geffen School of Medicine at UCLA.

“Given the facts of transmission, eradication of polio is a misnomer. While polio had been eradicated in the U.S., Afghanistan and Pakistan still have not eliminated the disease, and two years ago, it was imported to East Africa,” he says.

“Since there are still pockets of the disease in the world, there is always a risk, and it has happened before that the virus is brought into the country by international travelers.”

Sep 20, 2022

"Twindemic is like a naturally occurring biological weapon against humanity. There are several pharmaceutical therapies in development that have shown great promise in treating a potential twindemic, Pentarlandir® being one." Emil Tsai, MD, PhD, SyneuRx CEO